ICH Guidelines

ICH E8(R1) - General Considerations for Clinical Studies

Plain-language explanation, inspection context and common violation patterns.

What it says

This guideline sets out general principles for planning and conducting clinical studies, emphasizing a quality by design approach in which the factors critical to the quality of a study are identified early and managed proportionately to the risk to participants and to the reliability of results.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

It brings the risk-based thinking familiar from manufacturing quality, in the ICH Q8 to Q10 family, into clinical study design.
Identifying critical to quality factors up front allows effort to be focused where it protects participants and data reliability.
It works hand in hand with the GCP guideline, ICH E6(R3), which covers conduct of trials.

What inspectors look for

Whether critical to quality factors were identified and addressed in the study design and oversight.
Whether risk-proportionate oversight is documented and matches how the study was run.
Whether study conduct is consistent with the protocol and GCP expectations.

Most common violation

A study with no documented identification of the factors critical to participant protection and data reliability, so oversight is not focused on them.

Related regulations

Want a deeper, interactive breakdown?

GMPify's Regulation Explainer tool gives subscribers an AI-powered analysis of any 21 CFR, EU GMP, USP or ICH reference, with live inspection context.

Try the Regulation Explainer →